FMW Media’s New to The Street announces the broadcasting of its
business show broadcasting as a sponsored program on Bloomberg TV,
October 13, 2022, at 9:30 PM PT.
New to The Street’s TV show will air the following
five (5) business interviews:
1). PetVivo Holdings, Inc.’s (NASDAQ: PETV)
(NASDAQ: PETVW) ($PETV) interview with John Lai, CEO &
President.
2). Mikra Cellular Sciences’ (a division of Lifeist
Wellness, Inc.) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS:
NXTTF) interview with Faraaz Jamal, CEO, Mikra Cellular
Sciences & COO, Lifeist Wellness, Inc.
3). Sekur Private Data, Ltd.’s (OTCQX:
SWISF) (CSE: SKUR) (FRA: GDT0) interview with Mr. Alain Ghiai,
CEO.
4). The Sustainable Green Team’s (OTC: SGTM)
($SGTM) interviews with Tony Raynor, CEO, and Brian Rivera,
Administrative Assistant.
5). Tonix Pharmaceuticals, Inc.’s (NASDAQ:
TNXP) ($TNXP) interview with Dr. Seth Lederman, MD, and CEO.
Episode #395
New to The Street TV is airing the Nasdaq
Marketplace studio interview with John Lai, CEO /
President PetVivo Holdings,
Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV).
The Company is a biomedical device company that manufactures,
commercializes, and licenses innovative medical devices and
therapeutics for companion animals. Talking with TV Host Jane King,
John gives viewers an update on the recent launch of the
distribution agreement between PETV and MWI Animal Health (MWI), a
leading animal health products and services distributor, and
Amerisource Bergen subsidiary. With over $5B in annual revenue, MWI
is one of the largest distributors of veterinary drugs and
products, with lots of business resources and skilled personnel.
Securos is the educational division at MWI, which provides
hands-on-training, resources, and continuing education for
veterinarians, helping them understand the full benefits of
products. The educational and sales/ market teams at MWI now
promote and distribute PETV’s injectable patented Spryng with
OsteoCushion Technology that treats osteoarthritis and joint
afflictions for dogs, horses, and cats. As a naturally derived
product, Spryng mimics collagen tissue that significantly improves
animals’ afflicted joints. The feline osteoarthritis version of
Spryng is coming to market soon. John says the Spryng roll-out with
MWI is going very well. Recently, PETV hired more seasoned
personnel with over two decades of sales/marketing experience in
the pet industry. The on-screen QR code is available during the
show; download or visit PetVivo Holdings,
Inc. - https://petvivo.com/ and Spryng with
OsteoCushion Technology -
https://www.sprynghealth.com/.
New to The Street airs TV Host Jane King’s Nasdaq
Marketplace interview with Faraaz Jamal, CEO of Mikra Cellular
Sciences ("Mikra") and COO of Lifeist Wellness, Inc. (TSXV: LFST)
(FRANKFURT: M5B) (OTCMKTS: NXTTF). Faraaz provides viewers with an
update Mikra's operations and on its CELLF™ product that enhances
humans' microscopic cellular activities. Demand is up as product
acceptance continues, gaining more customers, and Mikra continues
to increase production output to meet this demand. Faraaz talks
about clinical studies on CELLF with data suggesting that the
nutraceutical can offset the issues associated with Chronic Fatigue
Syndrome (CFS), known as "Brain Fog.” Many with long-Covid
afflictions complain about "Brain Fog," with many physicians not
understanding the best way to treat the problem. CELLF is a product
with high concentrations of organic minerals and vitamins that
target cellular activities through Mikra's novel cellular delivery
system. CELLF is a nutraceutical gel with a buttery-type
consistency, produced in small batches to ensure quality control
standards that eliminate oxidation issues common with competitor
products. Determined to change health care practices, which account
for treatments after illness onset, Faraaz believes preventative
products like CELLF can produce long-lasting good health. More
products are in the Mikra pipeline, one of which is soon to come to
market, an athletic product designed to increase workouts and
decrease recovery times from solid performances. If you wake up
after 8 hours of sleep feeling sluggish and seem to lose energy
midday, CELLF could be the answer. Mikra sells its product through
its e-commerce outlets. Mikra Cellular Sciences is a Lifeist
Wellness, Inc. subsidiary that develops, produces, and sells
bioactive consumer products. The on-screen QR code is available
during the show; download or visit Mikra Cellular Sciences -
https://wearemikra.com/.
On the New to The Street show, Alain Ghiai,
CEO, Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA:
GDT0) ($SWISF) (Sekur®), gives TV Host Jane King and viewers an
overview of Sekur Private Data, Ltd.'s Sekur® cybersecurity
products and talks about hacking problems coming out of North
Korea. The North Koreans are attacking LinkedIn with posts full of
malware to steal data. You think you are getting a business
referral, so you hit the link, and your device becomes compromised.
Years ago, open-source platforms allowed software developers to
share code creating usable solutions to grow the reaches of
technology. It was an acceptable method at the time, but now,
open-source platforms, the majority used by "Big Tech," are where
stolen code gets manipulated; favorite ways for hackers to create a
nefarious campaign to steal data. Be careful about all those
supposed "Free-Apps"; a virus code is waiting to infect your
devices. Sekur is a closed-loop platform with an encryption layer
of security not available using open-platform products. SekurMail
and SekurMessenger, along with its other cybersecurity products,
Sekur can offer its end-users a complete privacy solution. Because
Sekur operates on a closed-source platform, code is unavailable for
hackers to manipulate. Many understand the benefits of subscribing
to Sekur's software solutions, which shows in the Company's
financial results. Alian expects financial results in Q3 to be
higher than Q2 from the increases in subscribers for its email,
text, and other encrypted platforms. The Company lowered marketing
expenses, and management believes its Q4 results should continue to
be strong from subscriber increases. The Fundamental Research
Report (FRC Report), dated September 8, 2022, provides a
comprehensive report about the Company's current and future
operational status. Sekur entered into a number of partnerships and
the results from these agreements should show in financial results
in Q1 2023. Alain sees more upside growth in 2023 and anticipates
net profitability in 2025. Sekur Private Data, Ltd. hosts its
services in Switzerland, benefiting from the stringent Swiss
Privacy laws. It uses a closed-source proprietary technology on an
independent and military-grade encrypted platform. The on-screen QR
code is available during the show; download or visit Sekur Private
Data, Ltd. – https://www.sekurprivatedata.com/ and
http://www.Sekur.com. Peer to peer, end to end, secure suite,
password manager, mail txt and video conference secure.
New to the Street's TV Host Jane King interviews
The Sustainable Green Team’s (OTC: SGTM) Tony Raynor, CEO, and
Brian Rivera, Administrative Assistant. From the Nasdaq Marketplace
studio, Tony explains the Company's business in providing
eco-friendly and sustainable solutions for several industries. As a
holding Company with many wholly-owned subsidiaries, SGTM can
develop and deploy innovative solutions to mitigate waste and other
byproducts. For 35 years, one of SGTM's subsidiaries was the first
to take naturally occurring iron oxide pigments and formulate
colored mulch products. Other sustainable solutions and products
continue at SGTM multiple locations because of its management's
strong leadership and dedicated team. SGTM successfully works with
municipalities in arbor culture and storm recovery, creating
comprehensive waste solutions. From the abundance of green waste
worldwide, SGTM can handle the waste making it into usable and
friendly products. SGTM creates soils, mulches, and lumber products
from green reusable waste. Brian talks about all the excitement
coming from within the Company, its subsidiaries, and from external
sources in creating and utilizing eco-friendly solutions and
products. People just want to get involved in restoring and
creating a green world. Cutting-edge technologies are from the
visionaries who are pioneering new solutions to create cleaner
outcomes for the planet. The Company entered into collaboration
with an Australian company, VRM BioLogik Group which developed a
product that creates water from organics. SGTM’s management will
continue to aggressively seek partnerships with like-minded
individuals and entities to find more environmentally sustainable
solutions and products. The on-screen QR code is available during
the show; download or visit The Sustainable Green Team -
https://www.thesustainablegreenteam.com/.
Dr. Seth Lederman, MD, CEO of Tonix
Pharmaceuticals, Inc. (NASDAQ: TNXP) ($TNXP), is at the Nasdaq
Marketplace studio, talking with New to The Street's TV Host Jane
King. As a clinical-stage biopharmaceutical Company, Seth informs
viewers that the FDA approved an IND clearance for TNX-601 for
human depression. The Company is developing a time-released pill, a
once-a-day dose, as a new first-line potential treatment for those
inflicted with depression. The pill's formulation uses the compound
tianeptine. Europe, Latin America, and Asia countries for about
30-years used this compound to treat those depressed. TNXP
anticipates moving TNX-601's IND stage forward to a Phase 2 trial
sometime beginning of next year, 2023. Tonix has many pipeline
drugs in development. Its led product TNX-102 SL completed its
first part of the Fibromyalgia FDA Phase 3 clinical trial and is
moving forward with the all the necessary FDA rules expecting to
achieve a new drug approval status. Two-thirds of Long-Covid
patients have multi-site pain, similar to those who have
Fibromyalgia. Tonix is moving forward with an FDA Phase 2
Long-Covid prevail study for its TNX-102 SL. Also, those with
Chronic Fatigue Syndrome (CFS) could use TNX-102SL if approved to
treat accordingly. Tonix Pharmaceuticals is developing many drugs
to treat central nervous system disorders and diseases. The
on-screen QR code is available during the show; download or visit
Tonix Pharmaceuticals, Inc. - https://www.tonixpharma.com/.
About PetVivo Holdings,
Inc. (NASDAQ: PETV) (NASDAQ: PETVW)
($PETV):
PetVivo Holdings Inc. (NASDAQ: PETV) (NASDAQ:
PETVW) ($PETV) is an emerging biomedical device company focused on
manufacturing, commercializing, and licensing innovative medical
devices and therapeutics for companion animals. The Company’s
strategy is to leverage human therapies for treating companion
animals cost-effectively and time-efficiently. A vital component of
this strategy is the accelerated timeline to revenues for
veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of
animals and people. A portfolio of nineteen patents protects the
Company’s biomaterials, products, production processes, and methods
of use. The Company’s lead product SPRYNG™ with
OsteoCushion™ technology, a veterinarian-administered,
intraarticular injection for the management of lameness and other
joint-related afflictions, including osteoarthritis, in dogs and
horses, is currently available for commercial sale -
https://petvivo.com/.
About Mikra Cellular
Sciences:
Mikra Cellular Sciences ("Mikra"), a division of
Lifeist Wellness, Inc. (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS:
NXTTF), is a breakthrough Company seeking to unlock cellular
potential and maximize the health of humans. Mikra intends to
bridge the scientific gap between cellular health and consumer
wellness and focuses on ones’ health at the cellular level.
Human cells are responsible for the overall functionality of human
biology. Mikra continues to develop products that can enhance
cellular absorption of key and need minerals and nutrients to
improve health and wellness. CELLF™ product is clinically tested
and engineered to bring balance to the body and mind on a cellular
level -https://wearemikra.com/. Lifeist Wellness, Inc. (TSXV: LFST)
(FRANKFURT: M5B) (OTCMKTS: NXTTF) is sitting at the forefront of a
post-pandemic wellness revolution, leveraging the advancements in
science and technology to build breakthrough companies that
transform human wellness. Its business portfolio includes:
CannMart, a B2B wholesale distribution business that facilitates
recreational cannabis sales to Canadian provincial government
control boards; CannMart Labs, a BHO extraction facility for the
production of high-margin cannabis 2.0 products;
the CannMart.com marketplace, which provides US customers
with access to hemp-derived CBD and smoking accessories; Australian
Vapes, the country's largest online retailer of vaporizers and
accessories; Findify, a leading AI-powered search-and-discovery
platform; and Mikra, a biosciences and consumer wellness company
seeking to develop innovative therapies for cellular health.
Information on Lifeist and its businesses - www.lifeist.com,
www.cannmart.com, www.australianvaporizers.com.au,
www.wearemikra.com, and email: ir@lifeist.com.
About Sekur Private Data
Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA:
GDT0):
Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE:
SKUR) (FRA: GDT0) is a cybersecurity and internet privacy provider
of Swiss-hosted solutions for secure communications and secure data
management. The Company distributes encrypted emails, secure
messengers, secure communication tools, secure cloud-based storage,
disaster recovery, and document management products. The Company
sells and serves consumers, businesses, and governments worldwide
through approved wholesalers, distributors, and telecommunications
companies. Contact Sekur Private Data, Ltd. at
corporate@globexdatagroup.com or
visit https://www.sekurprivatedata.com and https://www.sekur.com.
About The Sustainable
Green Team, Ltd. (OTC: SGTM)
($SGTM)
The Sustainable Green Team, Ltd. (OTC: SGTM)
($SGTM) is an emerging provider of environmentally beneficial
solutions for preserving natural resources and the municipal waste
and recycling industries. The Company is a wholesale manufacturer
and supplier of wood-based mulch and lumber products, primarily in
the Midwest, Southeast, and Ohio Valley regions. The Company also
provides arbor care and storm recovery services to municipalities,
corporations, and consumers, primarily in the southeastern United
States. The Company plans to expand its operations through organic
growth and strategic acquisitions that are both accretive to
earnings and positioned for rapid growth from the resulting
synergistic opportunities identified. The Company’s customers
include governmental, residential and commercial clients -
https://www.thesustainablegreenteam.com/
About Tonix
Pharmaceuticals Holding Corp. (NASDAQ: TNXP)
($TNXP):
Tonix Pharmaceuticals Holding Corp. (NASDAQ:
TNXP) ($TNXP) is a clinical-stage biopharmaceutical company focused
on discovering, licensing, acquiring, and developing small
molecules and biologics to treat and prevent human disease and
alleviate suffering. Tonix’s portfolio comprises immunology, rare
disease, infectious disease, and central nervous system (CNS)
product candidates. Tonix’s immunology portfolio includes biologics
to address organ transplant rejection, autoimmunity, and cancer.
TNX-15001 is a humanized monoclonal antibody targeting CD40-ligand
in development to prevent allograft and xenograft rejection and
treat autoimmune diseases. A Phase 1 study of TNX-1500 is expected
to be initiated in the second half of 2022. Tonix’s rare disease
portfolio includes TNX-29002 for the treatment of Prader-Willi
syndrome. The FDA has granted TNX-2900 Orphan-Drug Designation.
Tonix’s infectious disease pipeline consists of a vaccine in
development to prevent smallpox and Monkeypox called TNX-8013,
next-generation vaccines to prevent COVID-19, and an antiviral to
treat COVID-19. Tonix’s lead vaccine candidates for COVID-19 are
TNX-1840 and TNX-18504, live virus vaccines based on Tonix’s
recombinant pox vaccine (RPV) platform. TNX-35005
(sangivamycin, i.v. solution) is a small molecule
antiviral drug to treat acute COVID-19 and is in the pre-IND stage
of development. TNX-102 SL, (cyclobenzaprine HCl sublingual
tablets) is a small molecule drug being developed to treat Long
COVID, a chronic post-acute COVID-19 condition. Tonix expects to
initiate a Phase 2 study in Long COVID in the second quarter of
2022. The Company’s CNS portfolio includes small molecules and
biologics to treat pain, neurologic, psychiatric and addiction
conditions. Tonix’s lead CNS candidate, TNX-102 SL, is in mid-Phase
3 development to manage fibromyalgia, with a new Phase 3 study
launched in the second quarter of 2022. Finally, TNX-13006 is a
biologic designed to treat cocaine intoxication that is expected to
start a Phase 2 trial in the second quarter of 2022
- https://www.tonixpharma.com. (1TNX-1500 is an
investigational new biologic at the pre-IND stage of development
and has not been approved for any indication.2TNX-2900 is an
investigational new drug at the pre-IND stage of development and
has not been approved for any indication.3TNX-801 is a live
horsepox virus vaccine for percutaneous administration in
development to protect against smallpox and Monkeypox. TNX-801 is
an investigational new biologic and has not been approved for any
indication.4TNX-1840 and TNX-1850 are live horsepox virus vaccines
for percutaneous administration, in development to protect against
COVID-19. TNX-1840 and TNX-1850 are designed to express the
SARS-CoV-2 spike protein from the omicron and BA.2 variants,
respectively. TNX-1840 and TNX-1850 are investigational new
biologics at the pre-IND stage of development and have not been
approved for any indication. 5TNX-3500 is an investigational new
drug at the pre-IND stage of development and has not been approved
for any indication.6TNX-1300 is an investigational new biologic and
has not been approved for any indication.)
About FMW Media:
FMW Media operates one of the longest-running US
and International sponsored and Syndicated Nielsen Rated
programming television brands, "New to The Street," and its
blockchain show, "Exploring The Block." Since 2009, these brands
have run biographical interview segment shows across major U.S.
television networks. The paid-for-television programming platforms
can potentially reach over 540 million homes in the US and
international markets. FMW's New to The Street / Newsmax televised
broadcasting platform airs its syndication on Sundays at 10 -11 AM
ET. FMW is also one of the nation's largest buyers of linear
television, long and short-form paid programming
- https://www.newsmaxtv.com/Shows/New-to-the-Street & https://www.newtothestreet.com/.
Forward-Looking Statements
Disclaimer:
This press release contains forward-looking
statements within Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934. In
some cases, you can identify forward-looking statements by the
following words: "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "ongoing," "plan,"
"potential," "predict," "project," "should," "will," "would," or
the negative of these terms or other comparable terminology.
However, not all forward-looking statements contain these words.
Forward-looking statements are not a guarantee of future
performance or results and will not necessarily be accurate
indications of the times at which such performance or results are
achieved. This press release should be considered in all filings of
the Companies contained in the Edgar Archives of the Securities and
Exchange Commission at www.sec.gov.
CONTACT:
FMW Media Contacts: Bryan Johnson +1
(631) 766-7462 Bryan@NewToTheStreet.com
"New to The Street" Business Development Office
1-516-696-5900 Support@NewToTheStreet.com
A photo accompanying this announcement is available
at
https://www.globenewswire.com/NewsRoom/AttachmentNg/506703c3-e6ef-42c4-b1c1-4c683835c938
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Apr 2024 to May 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From May 2023 to May 2024